David D. Meek

CIK 1555337 · Chief Executive Officer · last filed 2026-06-18

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.87M

Companies

7

Total Filings

41

Lifetime Open-Market Net

-$696.9K

Filer Profile

Reported Address
C/O CULLINAN THERAPEUTICS INC
1 MAIN STREET SUITE 1350
CAMBRIDGE, MA 02142
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CGEM Director $20.57 $0 3 2026-06-18
QURE Director 41,740 $44.69 $1.87M -$220.6K 16 2026-06-12
Fusion Pharmaceuticals Inc. (FUSN) Delisted Director $21.55 $0 2 2024-06-04
Mirati Therapeutics, Inc. (MRTX) Delisted Chief Executive Officer 151,171 $58.70 $8.87M -$321.3K 5 2023-01-24
Entasis Therapeutics Holdings Inc. (ETTX) Delisted Director 0 $2.19 $0 $0 6 2022-07-11
Baxalta Inc (BXLT) Delisted EVP and President, Oncology 52,514 $0 3 2016-03-07
ENDOCYTE INC (ECYT) Delisted Chief Commercial Officer 7,500 -$155.0K 4 2014-02-10

Recent Filings · Page 3 of 5

41 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-02-15 Entasis Therapeutics Holdings Inc. (ETTX) Delisted Mixed $0 EDGAR
2022-01-19 Entasis Therapeutics Holdings Inc. (ETTX) Delisted Grant (A) +27,500 $0 EDGAR
2022-01-18 Mirati Therapeutics, Inc. (MRTX) Delisted Grant (A) +34,057 $0 EDGAR
2021-09-24 Mirati Therapeutics, Inc. (MRTX) Delisted Grant (A) $0 EDGAR
2021-04-02 Entasis Therapeutics Holdings Inc. (ETTX) Delisted Grant (A) +22,000 $0 EDGAR
2021-03-04 QURE Sell (S) −505 -$18.9K EDGAR
2021-03-01 QURE Grant (A) +2,382 $0 EDGAR
2020-10-06 Entasis Therapeutics Holdings Inc. (ETTX) Delisted Grant (A) $0 EDGAR
2020-03-02 QURE Grant (A) +2,063 $0 EDGAR
2020-01-30 QURE Sell (S) −722 -$44.9K EDGAR
Showing 2130 of 41
Page 3 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.